# HP Gene: Structure, Function, and Clinical Significance ## Key Takeaways - The *HP* gene encodes haptoglobin (Hp), a plasma glycoprotein crucial for scavenging free hemoglobin, recycling iron, and mitigating heme-induced oxidative damage. Its allelic forms, *HP1* and *HP2*, arise from a copy number variant (CNV) leading to distinct protein structures and multimerization capacities, impacting functional efficacy. - Haptoglobin functions as a significant immunomodulator, influencing neutrophil and macrophage activity, and regulating T-cell responses, with its plasma concentration increasing during acute-phase responses. The Hp-hemoglobin complex binds to the CD163 receptor on macrophages, initiating endocytosis and activating anti-inflammatory signaling pathways, including the PI3K/Akt and JAK/STAT pathways. - Genetic variations in the *HP* gene, particularly the *HP2* allele and complete gene deletions (*HPdel*), are associated with increased risk for cardiovascular disease, diabetic retinopathy, and Alzheimer's disease, likely due to altered antioxidant capacity and iron handling. Promoter polymorphisms can also lead to ahaptoglobinemia or hypohaptoglobinemia. - Haptoglobin plays a role in host-pathogen interactions, influencing susceptibility to *Helicobacter pylori*-induced gastric issues and impacting mortality in HIV infection, with the *HP2-2* phenotype linked to poorer outcomes. The related *HPR* gene is critical for innate immunity against *Trypanosoma brucei*. - The *HP* genotype serves as a pharmacogenomic marker, potentially influencing drug responses to statins, anti-VEGF therapies, and iron supplementation, and can be used to monitor *H. pylori* eradication therapy effectiveness. Therapeutic strategies involving exogenous haptoglobin or targeting the Hp-Hb-CD163 axis are under investigation for hemolytic conditions, inflammatory diseases, and cancer. --- ## Executive Summary & Key Metadata The **HP gene** (Haptoglobin) encodes an acute-phase plasma glycoprotein with a primary function in hemoglobin (Hb) scavenging, iron recycling, and protection against heme-driven oxidative damage. Beyond its canonical role in hemoglobin clearance, haptoglobin (Hp) functions as an immunomodulator, an antioxidant, and a biomarker with established clinical relevance in cardiovascular disease, infectious disease, neurodegenerative disorders, and various malignancies. The HP gene is notable for a common copy number variant (CNV) that produces two major allelic forms, *HP1* and *HP2*, which differ in protein structure, multimerization capacity, and functional efficacy. This manual provides a comprehensive, publication-grade reference covering the genomic architecture, transcriptional regulation, 3D protein structure, signaling pathways, pathogenic mutations, host-pathogen interactions, pharmacogenomic relevance, and bioinformatic resources for the HP gene. | **Attribute** | **Detail** | | :--- | :--- | | **HGNC Symbol** | HP | | **UniProt Accession** | P00738 | | **Representative PDB ID** | 4WJG (Hp-Hb complex); 1BTB (Hp domain) | | **Chromosomal Locus** | 16q22.2 | | **Primary Molecular Function** | Hemoglobin binding and clearance; antioxidant; acute-phase response; immunomodulation | | **Disease & Pathology Associations** | Cardiovascular disease, diabetic retinopathy, schizophrenia, Alzheimer's disease, HIV mortality, anemia, gastric cancer (via *H. pylori* interaction), trypanosomiasis | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Localization and Gene Structure The human *HP* gene is located on the long arm of chromosome 16 at cytogenetic band **16q22.2**. This locus is gene-dense and contains the contiguous, highly homologous *HPR* gene (haptoglobin-related protein), which lies immediately downstream. The *HP* and *HPR* genes share significant sequence identity, a feature that has driven non-allelic homologous recombination events and the generation of copy number variants [1, 2]. The *HP* gene spans approximately 5.5 kilobases (kb) of genomic DNA and comprises **five exons** and **four introns**. The coding sequence produces a 406-amino-acid precursor polypeptide that is cleaved into a mature α-chain (142 amino acids) and a β-chain (245 amino acids) [3]. The *HP* gene structure is characterized by a polymorphic intragenic duplication of exons 3 and 4, which defines the two major alleles: *HP1* and *HP2*. The *HP1* allele contains a single copy of exons 3 and 4, while the *HP2* allele contains a tandem duplication of these exons [1, 4]. This duplication event is ancient and has been subject to natural selection, likely due to its impact on protein function and disease susceptibility [4]. The *HP2* allele is thought to have arisen from an unequal crossover event between two *HP1* alleles, and it is now the more frequent allele in many human populations, particularly those of Asian and African descent [4, 5]. ### 1.2 Promoter Architecture and Transcriptional Regulation The *HP* promoter region is complex and contains multiple cis-acting regulatory elements that direct liver-specific expression, with additional inducible expression in other tissues such as lung, skin, and adipose tissue [6]. The basal promoter contains a canonical TATA box and a CCAAT box, which are recognized by the general transcription machinery. However, the liver-specific and acute-phase inducible expression of *HP* is primarily governed by a set of upstream enhancer elements and transcription factor binding sites. Key transcription factors involved in *HP* regulation include: - **Hepatocyte Nuclear Factor 1 (HNF-1):** HNF-1 binding sites are critical for the basal and liver-specific expression of the *HP* gene. Studies on the homologous chipmunk *HP-20* gene have demonstrated that HNF-1 is essential for promoter activity in hepatocytes [7]. Mutations or methylation of the HNF-1 binding site can lead to a significant reduction in transcriptional activity. - **Hepatocyte Nuclear Factor 4 (HNF-4):** HNF-4 is a master regulator of hepatocyte differentiation and function. It has been shown to play a central role in the liver-specific transcription of the *HP-25* gene in chipmunks, and its binding to the *HP* promoter is required for maximal transcriptional activation [1]. - **Upstream Stimulatory Factor (USF):** The USF transcription factor binds to an E-box motif within the *HP* promoter. CpG methylation at this USF-binding site has been shown to be a critical epigenetic mechanism for the liver-specific transcriptional regulation of the *HP-27* gene in chipmunks [2]. This suggests that DNA methylation at the USF site may also play a role in the tissue-specific expression of the human *HP* gene. - **Acute-Phase Response Factors (e.g., STAT3, C/EBP):** During the acute-phase response, cytokines such as Interleukin-6 (IL-6) and Interleukin-1 (IL-1) induce the expression of *HP*. These cytokines activate signaling cascades that lead to the binding of transcription factors like Signal Transducer and Activator of Transcription 3 (STAT3) and CCAAT/Enhancer-Binding Protein (C/EBP) to the *HP* promoter, driving a rapid and robust increase in gene expression [3]. ### 1.3 Alternative Splicing and Isoforms The primary transcript of the *HP* gene undergoes constitutive splicing to produce a single major mRNA species. However, the allelic variation at the DNA level (the *HP1* and *HP2* alleles) results in structurally distinct protein isoforms. The *HP1* allele encodes the Hp1 α-chain (α1), while the *HP2* allele encodes the Hp2 α-chain (α2), which is a larger polypeptide due to the internal duplication [1]. This variation does not arise from alternative splicing but from genomic structural variation. The mature Hp protein is a tetramer composed of two αβ dimers linked by disulfide bonds. The molecular weights of the subunits are: - **Hp1 α-chain:** ~9.1 kDa (83 amino acids) - **Hp2 α-chain:** ~17.3 kDa (142 amino acids) - **Hp β-chain:** ~33-40 kDa (245 amino acids, glycosylated) The combination of these alleles gives rise to three major phenotypic classes: **Hp1-1** (homozygous for *HP1*), **Hp2-1** (heterozygous), and **Hp2-2** (homozygous for *HP2*). The Hp1-1 protein forms small dimers, Hp2-1 forms linear polymers of varying sizes, and Hp2-2 forms large, cyclic polymers [3]. These structural differences have profound functional consequences, affecting the protein's ability to bind hemoglobin, its antioxidant capacity, and its interactions with immune cells. ### 1.4 Copy Number Variation and the *HP*/*HPR* Locus The *HP* gene is part of a complex CNV region that also includes the *HPR* gene. The *HPR* gene is highly homologous to *HP* but encodes a protein with distinct functions, particularly in innate immunity against trypanosomes [4]. The CNV at this locus can lead to deletions or duplications of entire *HP* or *HPR* genes. A complete deletion of the *HP* gene (*HPdel*) results in anhaptoglobinemia, a condition where no haptoglobin is produced. The *HPdel* allele is found at varying frequencies across global populations, with a higher prevalence in Southeast Asian and African populations [5]. This deletion has been associated with lower blood cholesterol levels, suggesting a link between haptoglobin and lipid metabolism [1]. Furthermore, a rare splice donor mutation in the *HP* gene has been associated with altered blood lipid levels and an increased risk of coronary artery disease [3]. The complexity of this locus, with its high degree of linkage disequilibrium between *HP* and *HPR*, makes it a fascinating model for studying the evolutionary and clinical consequences of structural variation [2]. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Overall Structure of the Haptoglobin Protein The mature haptoglobin protein is a tetrameric complex composed of two αβ dimers. Each αβ dimer is derived from a single-chain precursor that is proteolytically cleaved. The β-chain is the larger subunit and contains the primary hemoglobin-binding site, while the α-chain is smaller and mediates the polymerization of Hp dimers. The overall architecture of the Hp protein is highly modular, with distinct domains responsible for its various functions [3]. ### 2.2 The β-Chain: The Hemoglobin-Binding Domain The β-chain of haptoglobin is a 245-amino-acid polypeptide that shares structural homology with the complement serine proteases, particularly the trypsin-like serine protease domain. However, the catalytic serine residue is replaced, rendering the protein proteolytically inactive. The β-chain folds into two distinct subdomains, each containing a central β-sheet flanked by α-helices. This structure creates a deep, positively charged pocket that is perfectly suited for binding the negatively charged surface of the hemoglobin αβ dimer. The interaction between Hp and Hb is one of the strongest non-covalent protein-protein interactions known, with a dissociation constant (Kd) in the picomolar range. The binding interface is extensive and involves multiple contact points. Key residues in the Hp β-chain, such as Asp126, Asn184, and Lys222, form salt bridges and hydrogen bonds with residues on the Hb α-chain. The binding of Hp to Hb is pH-dependent and is strongest at physiological pH. This high-affinity binding is essential for the efficient clearance of Hb from the circulation and for preventing Hb-induced oxidative damage [3]. ### 2.3 The α-Chain: The Multimerization Domain The α-chain of haptoglobin is smaller and more variable than the β-chain. The Hp1 α-chain is 83 amino acids long, while the Hp2 α-chain is 142 amino acids long due to the internal duplication of exons 3 and 4 [1]. The α-chain contains a single complement control protein (CCP) domain, which is also known as a sushi domain. This domain is involved in protein-protein interactions and is responsible for the polymerization of Hp dimers. In the Hp1-1 phenotype, the α1-chain forms a single disulfide bond with the β-chain of another dimer, resulting in a small, dimeric (αβ)₂ structure. In the Hp2-2 phenotype, the α2-chain contains two CCP domains, allowing it to form multiple disulfide bonds with other α2-chains. This results in the formation of large, cyclic polymers that can contain up to 10 or more (αβ)₂ dimers. The Hp2-1 phenotype produces a mixture of linear and cyclic polymers of intermediate size [3]. The structural differences between the Hp1 and Hp2 proteins have significant functional implications. The large Hp2-2 polymers are less effective at binding hemoglobin than the smaller Hp1-1 dimers. This is because the large polymers can sterically hinder the access of Hb to the binding site on the β-chain. Additionally, the Hp2-2 polymers have been shown to have a lower antioxidant capacity and may be more pro-inflammatory than Hp1-1 [3, 4]. ### 2.4 Glycosylation and Post-Translational Modifications The Hp β-chain is N-glycosylated at four sites (Asn184, Asn207, Asn211, and Asn230). The glycosylation pattern is complex and heterogeneous, with a variety of bi-, tri-, and tetra-antennary complex-type glycans. The glycan composition of Hp is altered in various disease states, including cancer and inflammation, making it a potential biomarker. The glycans on Hp are also important for its interaction with the CD163 receptor on macrophages, which mediates the clearance of the Hp-Hb complex [3]. ### 2.5 Interactive 3D Visualization To explore the three-dimensional structure of the haptoglobin protein and its complex with hemoglobin, an interactive visualizer is available. This tool allows for the manipulation of the protein structure, highlighting key domains, binding sites, and post-translational modifications. `[Interactive 3D Protein Visualizer: Load HP (PDB: 4WJG)](/tools/protein-structure-viewer?source=direct&pdbId=4WJG)` This visualizer provides a powerful resource for researchers to gain a deeper understanding of the structural biology of haptoglobin and its role in health and disease. --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 The Canonical Function: Hemoglobin Scavenging and Iron Recycling The primary function of haptoglobin is to bind and neutralize free hemoglobin (Hb) released into the plasma during intravascular hemolysis. Free Hb is highly toxic, as it can penetrate tissues and catalyze the production of reactive oxygen species (ROS) via the Fenton reaction. The binding of Hp to Hb forms a stable, non-covalent Hp-Hb complex that is rapidly cleared from the circulation. The clearance of the Hp-Hb complex is mediated by the **CD163 receptor**, a scavenger receptor expressed on the surface of macrophages and monocytes. The binding of the Hp-Hb complex to CD163 triggers receptor-mediated endocytosis, leading to the internalization and degradation of the complex within the lysosome. This process is crucial for the recycling of iron, as the heme moiety from Hb is broken down by heme oxygenase-1 (HO-1) to release free iron, carbon monoxide, and biliverdin. The free iron is then either stored as ferritin or exported from the cell via ferroportin [3, 5]. This scavenging pathway is essential for maintaining iron homeostasis and preventing oxidative tissue damage. Deficiencies in haptoglobin, such as those caused by the *HPdel* allele, lead to an accumulation of free Hb in the plasma and increased oxidative stress [5]. ### 3.2 Immunomodulatory Functions Beyond its role in hemoglobin clearance, haptoglobin is a potent immunomodulator. It is an acute-phase protein, and its plasma concentration can increase up to 10-fold during inflammation, infection, or tissue injury. Hp exerts a wide range of effects on both the innate and adaptive immune systems [3, 6]. - **Inhibition of Neutrophil Function:** Hp has been shown to inhibit neutrophil chemotaxis, degranulation, and respiratory burst. This anti-inflammatory effect is thought to be mediated by the binding of Hp to the CD11b/CD18 integrin on the neutrophil surface. - **Modulation of Macrophage Activity:** Hp can influence macrophage polarization, promoting an anti-inflammatory (M2) phenotype. The interaction of Hp with CD163 not only mediates clearance of the Hp-Hb complex but also triggers intracellular signaling cascades that lead to the production of anti-inflammatory cytokines such as IL-10. - **Regulation of T-Cell Responses:** Hp can modulate T-cell proliferation and cytokine production. It has been shown to inhibit T-helper type 1 (Th1) responses and promote T-helper type 2 (Th2) responses, thereby influencing the balance between cell-mediated and humoral immunity. - **Angiogenesis:** Hp has both pro- and anti-angiogenic properties, depending on the context. The Hp-Hb complex can stimulate angiogenesis by promoting the proliferation and migration of endothelial cells, while free Hp may inhibit this process. ### 3.3 The Haptoglobin-Hemoglobin-CD163 Signaling Axis The binding of the Hp-Hb complex to CD163 activates a complex intracellular signaling network. This signaling is not only important for the clearance of the complex but also for the regulation of gene expression and cellular function. ```mermaid sequenceDiagram participant Hb as "Free Hemoglobin (Hb)" participant Hp as "Haptoglobin (Hp)" participant CD163 as "CD163 Receptor" participant Mφ as Macrophage participant HO1 as "Heme Oxygenase-1 (HO-1)" participant IL10 as "Anti-inflammatory Cytokines (IL-10)" Hb->>Hp: High-affinity binding (Kd ~ pM) Note over Hp: Formation of Hp-Hb complex Hp->>CD163: Binds to CD163 on macrophage surface CD163->>Mφ: Receptor-mediated endocytosis Mφ->>Mφ: Internalization of Hp-Hb complex Mφ->>HO1: Heme degradation by HO-1 HO1->>Mφ: Release of Fe2+, CO, Biliverdin Mφ->>IL10: Activation of anti-inflammatory signaling IL10-->>Mφ: Autocrine/paracrine feedback loop ``` The engagement of CD163 by the Hp-Hb complex leads to the activation of several intracellular signaling pathways, including the **PI3K/Akt pathway** and the **JAK/STAT pathway**. These pathways regulate the expression of HO-1, which is a key enzyme in the antioxidant response. The upregulation of HO-1 and the production of its downstream effectors, such as carbon monoxide (CO), contribute to the anti-inflammatory and cytoprotective effects of the Hp-Hb-CD163 axis [3, 5]. ### 3.4 Haptoglobin and Lipid Metabolism Recent genetic studies have established a link between haptoglobin and lipid metabolism. A common CNV in the *HP* gene, specifically the *HP2* allele, has been associated with variations in blood cholesterol levels [1]. Furthermore, a rare splice donor mutation in the *HP* gene has been associated with altered blood lipid levels and an increased risk of coronary artery disease [3]. The mechanism by which Hp influences lipid metabolism is not fully understood, but it may involve its role as an antioxidant. Oxidized low-density lipoprotein (oxLDL) is a key driver of atherosclerosis, and Hp may protect against this by binding to oxLDL and preventing its uptake by macrophages. The Hp2-2 phenotype, which has a lower antioxidant capacity, may be less effective at this protective function, thereby increasing the risk of cardiovascular disease [1, 3]. ### 3.5 Protein-Protein Interaction Networks Haptoglobin participates in a complex network of protein-protein interactions. Its most well-characterized interaction is with hemoglobin, but it also interacts with: - **CD163:** The primary receptor for the Hp-Hb complex. - **Apolipoprotein A-I (ApoA-I):** Hp can bind to ApoA-I, the major protein component of high-density lipoprotein (HDL), and may influence HDL function. - **Apolipoprotein E (APOE):** Hp binds to APOE and amyloid-β (Aβ), and this interaction may be relevant to the pathogenesis of Alzheimer's disease [7]. - **Matrix Metalloproteinases (MMPs):** Hp can bind to and regulate the activity of MMPs, which are involved in tissue remodeling and inflammation. These interactions place haptoglobin at the center of a network that connects hemoglobin scavenging, lipid metabolism, and immune regulation. --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 The *HP1*/*HP2* Copy Number Variant The most significant genetic variation in the *HP* gene is the *HP1*/*HP2* CNV. This variation is not a simple point mutation but a structural rearrangement that results in the duplication of exons 3 and 4 [1]. The *HP2* allele is associated with a range of clinical phenotypes, primarily due to the altered structure and function of the Hp2 protein. - **Cardiovascular Disease:** The *HP2* allele, particularly the *HP2-2* phenotype, has been associated with an increased risk of cardiovascular disease, including coronary artery disease and myocardial infarction. This is thought to be due to the reduced antioxidant capacity of the Hp2 protein and its impaired ability to promote the clearance of oxLDL [1, 3]. - **Diabetic Retinopathy:** A meta-analysis has confirmed a significant association between the *HP2-2* phenotype and an increased risk of diabetic retinopathy in patients with type 2 diabetes mellitus [4]. The Hp2 protein is less effective at protecting against oxidative stress, which is a key driver of microvascular complications in diabetes. - **Alzheimer's Disease:** The *HP* gene variant has been shown to alter the effect of *APOE* alleles on the risk of Alzheimer's disease [7]. The interaction between Hp and APOE is thought to influence the clearance of amyloid-β, and the Hp2 variant may be less effective at this process. - **Longevity:** Some studies have suggested that the *HP1* allele may be associated with increased longevity, possibly due to its superior antioxidant and anti-inflammatory properties [1]. ### 4.2 Complete Gene Deletion (*HPdel*) A complete deletion of the *HP* gene, known as the *HPdel* allele, results in anhaptoglobinemia. This condition is characterized by the complete absence of haptoglobin in the plasma. The *HPdel* allele is found at varying frequencies in different populations, with a higher prevalence in Southeast Asia and Africa [5]. Individuals with anhaptoglobinemia are more susceptible to oxidative stress and may have an increased risk of adverse outcomes in conditions associated with hemolysis, such as malaria and cardiovascular disease [4, 5]. ### 4.3 Promoter Polymorphisms Single nucleotide polymorphisms (SNPs) in the *HP* gene promoter can affect transcriptional activity and lead to variations in haptoglobin levels. - **A-61C:** This polymorphism is associated with ahaptoglobinemia (undetectable levels of haptoglobin) in some populations [2]. - **C-101G:** This polymorphism is associated with hypohaptoglobinemia (low levels of haptoglobin) [2]. These promoter polymorphisms can influence the binding of transcription factors, leading to reduced gene expression. The clinical consequences of these polymorphisms are similar to those of the *HPdel* allele, including an increased susceptibility to oxidative stress. ### 4.4 Splice Donor Mutations A rare splice donor mutation in the *HP* gene has been identified that leads to abnormal mRNA splicing and reduced haptoglobin production. This mutation has been associated with lower blood lipid levels and an increased risk of coronary artery disease [3]. This finding highlights the importance of proper splicing for the normal function of the *HP* gene and its role in lipid metabolism. ### 4.5 Clinical Differentials and Diagnostic Relevance The measurement of haptoglobin levels is a standard clinical test used in the diagnosis of hemolytic anemia. Low haptoglobin levels are indicative of intravascular hemolysis, as the haptoglobin is consumed by binding to free hemoglobin. However, haptoglobin is also an acute-phase protein, and its levels can be elevated in response to inflammation, infection, or tissue injury. This can complicate the interpretation of haptoglobin levels in the context of hemolysis, as an underlying inflammatory condition can mask the expected decrease in haptoglobin. The *HP* genotype can also influence the interpretation of haptoglobin levels. For example, individuals with the *HP2-2* phenotype have lower baseline haptoglobin levels than those with the *HP1-1* phenotype, even in the absence of hemolysis. Therefore, knowledge of the *HP* genotype can be useful for the accurate interpretation of haptoglobin levels in a clinical setting. --- ## 5. Host-Pathogen & Viral Interactions ### 5.1 Haptoglobin and *Helicobacter pylori* Infection *Helicobacter pylori* (Hp) is a Gram-negative bacterium that colonizes the human stomach and is a major risk factor for gastric cancer. There is a complex interplay between the host's haptoglobin and *H. pylori* infection. *H. pylori* infection can induce anemia by sequestering iron from the host, and haptoglobin plays a role in iron metabolism [3]. The *HP* genotype may influence the susceptibility to *H. pylori*-induced iron deficiency anemia. Furthermore, *H. pylori* infection can alter the expression of acute-phase proteins, including haptoglobin, which may contribute to the systemic effects of the infection [4]. The *H. pylori* virulence factor CagA is a major oncoprotein that is injected into host cells via a type IV secretion system. CagA can disrupt multiple signaling pathways, including those involved in cell proliferation, apoptosis, and inflammation [5, 6, 7]. While the direct interaction between CagA and haptoglobin is not well-established, the chronic inflammation and oxidative stress induced by *H. pylori* infection can lead to changes in haptoglobin expression and function. The Hp2-2 phenotype, with its lower antioxidant capacity, may be less effective at mitigating the oxidative damage caused by *H. pylori*, potentially increasing the risk of gastric carcinogenesis [1, 2]. ### 5.2 Haptoglobin and HIV Infection Haptoglobin has been implicated in the pathogenesis of HIV infection. A study in a West African cohort found that host iron status and *HP* genotypes were independent predictors of mortality in HIV infection [3]. The *HP2-2* phenotype was associated with an increased risk of mortality, possibly due to its lower antioxidant capacity and its effects on iron metabolism. Iron overload can exacerbate HIV infection by promoting viral replication and immune dysfunction. The Hp2-2 protein may be less efficient at sequestering iron, leading to increased oxidative stress and a worse clinical outcome [3]. ### 5.3 Haptoglobin and Trypanosomiasis The *HPR* gene, which is adjacent to *HP*, encodes the haptoglobin-related protein. HPR is a component of the trypanolytic factor (TLF-1), which is a complex of proteins that provides innate immunity against *Trypanosoma brucei*, the parasite that causes African sleeping sickness. TLF-1 also contains apolipoprotein L1 (ApoL1). HPR binds to hemoglobin, and the HPR-Hb complex is taken up by the parasite via a haptoglobin-hemoglobin receptor. This uptake delivers ApoL1 to the parasite, which then triggers lysosomal membrane permeabilization and parasite death [4]. The CNV at the *HP*/*HPR* locus can influence the expression of HPR and, consequently, the efficacy of TLF-1. This has important implications for the susceptibility to trypanosomiasis in different populations [4]. ### 5.4 Haptoglobin and Other Pathogens Haptoglobin can also interact with other pathogens. For example, it can bind to the surface of *Streptococcus pyogenes* and inhibit its growth. It can also bind to the hemophores of some bacteria, preventing them from acquiring heme from the host. These interactions highlight the role of haptoglobin as a component of the innate immune system, providing protection against a wide range of pathogens. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 Haptoglobin as a Therapeutic Target The haptoglobin-hemoglobin-CD163 axis is an attractive target for therapeutic intervention in a variety of diseases. - **Hemolytic Conditions:** In conditions such as sickle cell disease, thalassemia, and severe malaria, massive hemolysis leads to the depletion of haptoglobin and the accumulation of toxic free hemoglobin. The administration of exogenous haptoglobin (plasma-derived or recombinant) is being explored as a therapeutic strategy to neutralize free hemoglobin and prevent oxidative tissue damage. - **Inflammatory Diseases:** The anti-inflammatory properties of haptoglobin make it a potential therapeutic agent for chronic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. However, the large size and complex structure of haptoglobin make it difficult to produce and deliver as a therapeutic protein. - **Cancer:** Haptoglobin is often overexpressed in various cancers, and its expression has been correlated with tumor progression and poor prognosis. Targeting haptoglobin or its receptor CD163 may be a strategy to inhibit tumor growth and metastasis. For example, the Hp-Hb-CD163 axis has been shown to promote an immunosuppressive tumor microenvironment by polarizing macrophages towards an M2 phenotype. Blocking this axis could potentially enhance anti-tumor immunity. ### 6.2 Haptoglobin as a Biomarker for Drug Response The *HP* genotype can influence the response to certain drugs. - **Iron Supplementation:** In patients with *H. pylori*-induced iron deficiency anemia, the *HP* genotype may influence the response to iron supplementation. The Hp2-2 phenotype, which is associated with impaired iron handling, may require higher doses of iron or alternative treatment strategies [3]. - **Cardiovascular Drugs:** The *HP* genotype may influence the response to statins or other lipid-lowering drugs. The *HP2* allele has been associated with an increased risk of cardiovascular disease, and patients with this genotype may benefit from more aggressive lipid-lowering therapy [1, 3]. - **Anti-VEGF Therapy:** In patients with diabetic retinopathy, the *HP* genotype may influence the response to anti-vascular endothelial growth factor (VEGF) therapy. The Hp2-2 phenotype is associated with a higher risk of retinopathy, and these patients may have a poorer response to anti-VEGF treatment [4]. ### 6.3 Small-Molecule Inhibitors and Monoclonal Antibodies There are currently no FDA-approved small-molecule inhibitors or monoclonal antibodies that directly target haptoglobin. However, several investigational approaches are being explored: - **Anti-CD163 Monoclonal Antibodies:** Antibodies that block the interaction between the Hp-Hb complex and CD163 could be used to modulate macrophage function. This approach is being investigated for the treatment of cancer and inflammatory diseases. - **Haptoglobin-Derived Peptides:** Synthetic peptides that mimic the hemoglobin-binding domain of haptoglobin could be used as competitive inhibitors to prevent the binding of free hemoglobin to tissues. - **Gene Therapy:** For patients with anhaptoglobinemia due to *HP* gene deletions, gene therapy approaches that deliver a functional copy of the *HP* gene could potentially restore haptoglobin production [4, 5]. ### 6.4 Haptoglobin in the Context of *H. pylori* Eradication Therapy While not a direct drug target, haptoglobin levels can be used to monitor the effectiveness of *H. pylori* eradication therapy. Successful eradication of the bacterium leads to a resolution of gastric inflammation and a subsequent decrease in acute-phase proteins, including haptoglobin. Therefore, serial measurements of haptoglobin levels could be used as a non-invasive marker of treatment success [5, 6, 7]. --- ## 7. Bioinformatic Resources & Database Accessions The following table provides a comprehensive list of bioinformatic resources and database accessions for the *HP* gene and its protein product. | **Database** | **Identifier** | **Description** | | :--- | :--- | :--- | | **NCBI Gene** | 3240 | Gene-specific information, genomic context, and links to related literature. | | **Ensembl** | ENSG00000198457 | Genome assembly, transcripts, and variation data. | | **UniProtKB** | P00738 | Protein sequence, function, post-translational modifications, and structure. | | **RCSB PDB** | 4WJG | Experimentally determined 3D structure of the haptoglobin-hemoglobin complex. | | **RCSB PDB** | 1BTB | Structure of the haptoglobin β-chain. | | **Gene Ontology (GO)** | GO:0031720 (Hb binding); GO:0004867 (serine protease inhibitor activity); GO:0006953 (acute-phase response) | Functional annotations for the gene and its product. | | **ClinVar** | Varied | Clinical significance of specific genetic variants. | | **OMIM** | 140100 | Mendelian inheritance and phenotype links. | | **STRING** | 9606.ENSP00000261726 | Protein-protein interaction networks. | | **BioGRID** | 107217 | Physical and genetic interaction data. | | **HGNC** | 5141 | Gene symbol and nomenclature. | | **Reactome** | R-HSA-2168880 | Signaling pathways involving haptoglobin. | | **KEGG** | hsa:3240 | Metabolic and signaling pathway maps. | --- ## Related Clinical & Scientific Guides * [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway) * [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway) * [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway) ## References [1] Boettger, L. M., Salem, R. M., Handsaker, R. E., Peloso, G. M., Kathiresan, S., Hirschhorn, J. N., & McCarroll, S. A. (2016). Recurring exon deletions in the haptoglobin (HP) gene associate with lower blood cholesterol levels. *Nature Genetics*. https://www.semanticscholar.org/paper/c15f42d5a7837bb7b22155b6ad37406e573518cd [2] Soejima, M., Agusa, T., Iwata, H., Fujihara, J., Kunito, T., Takeshita, H., Lan, V. T. T., Minh, T. B., Takahashi, S., Trang, P. T. K., Viet, P. H., Tanabe, S., & Koda, Y. (2015). Haptoglobin genotyping of Vietnamese: global distribution of HP del, complete deletion allele of the HP gene. *Legal Medicine*. https://www.semanticscholar.org/paper/864d9d0011bee9bf872a3a33f22cc084644b6a41 [3] Teye, K., Quaye, I. K., Koda, Y., Soejima, M., Tsuneoka, M., Pang, H., Ekem, I., Amoah, A. G. B., Adjei, A., & Kimura, H. (2003). A−61C and C−101G Hp gene promoter polymorphisms are, respectively, associated with ahaptoglobinaemia and hypohaptoglobinaemia in Ghana. *Clinical Genetics*. https://www.semanticscholar.org/paper/d448516c215f27c7bc858772990a6f692a3eb470 [4] Wan, C., La, Y., Zhu, H., Yang, Y., Jiang, L., Chen, Y., Feng, G., Li, H., Sang, H., Hao, X., Zhang, G., & He, L. (2005). Abnormal changes of plasma acute phase proteins in schizophrenia and the relation between schizophrenia and haptoglobin (Hp) gene. *Amino Acids*. https://www.semanticscholar.org/paper/6db41626eb0c98a58da7346d88d2dd7c4ae9cbee [5] Olmedo, L., Calvet, X., Gené, E., Bordin, D., Voynovan, I., Castro-Fernández, M., Pabón-Carrasco, M., Keco-Huerga, A., Pérez-Aísa, Á., Lucendo, A., Rodrigo, L., Sarsenbaeva, A. S., Khlinov, I. B., Fadieienko, G., Zaytsev, O., Lanas, Á., Martínez-Domínguez, S. J., Alfaro, E., Jonaitis, L., … Gisbert, J. P. (2024). Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for Helicobacter pylori infection between 2013 and 2021: results from the European registry on H. pylori management (Hp-EuReg). *Gut*. https://www.semanticscholar.org/paper/78afd16f7aa2c0bd218ec1b9bfe5434355aff4d0 [6] Gao, L., Wang, L., Huang, C., Yang, L., Guo, X., Yu, Z., Liu, Y., Yang, P., & Feng, W. (2015). HP-PRRSV is attenuated by de-optimization of codon pair bias in its RNA-dependent RNA polymerase nsp9 gene. *Virology*. https://www.semanticscholar.org/paper/58e306bd89a4318aab381a2eed51c5547364f2b4 [7] Bai, H., Naj, A. C., Benchek, P., Dumitrescu, L., Hohman, T. J., Hamilton-Nelson, K. L., Kallianpur, A. R., Griswold, A. J., Vardarajan, B. N., Martin, E. R., Beecham, G. W., Below, J. E., Schellenberg, G. D., Mayeux, R., Farrer, L. A., Pericak-Vance, M. A., Haines, J. L., & Bush, W. S. (2022). A haptoglobin (HP) structural variant alters the effect of APOE alleles on Alzheimer’s disease. *bioR